# A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Source: https://onco.cc/trials/nct07459634/  
OnCo record `nct07459634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lurbinectedin, Durvalumab in small-cell lung cancer, run by Jazz Pharmaceuticals, now recruiting.

## Summary

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC is a phase 2 interventional study registered as NCT07459634 by Jazz Pharmaceuticals, with 50 participants planned, started 2026-11-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: Lurbinectedin, Durvalumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07459634
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab
- Sponsor: Jazz Pharmaceuticals
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07459634: https://clinicaltrials.gov/study/NCT07459634

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/)
- companies: [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/)

---
JSON: https://onco.cc/api/v1/entities/nct07459634.json